Sinusitis Treatment Gets Fast Track Status from FDA (Amphotericin B)

[Guest guest]

New Sinusitis Treatment Gets Fast Track Status from FDA

SinuNase, an intranasal Amphotericin B formulation by Accentia

Biopharmaceuticals for the treatment of chronic sinusitis, has been given Fast

Track status by the U.S. Food and Drug Administration.

According to Accentia, SinuNase is the first and only drug candidate for chronic

sinusitis to receive Fast Track status from the FDA... Click here to read the

entire article.

Direct URL: http://www.newsdial.com/sinusitis/sinusitis-treatment-fda.html

penny